Related references
Note: Only part of the references are listed.EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Friedhelm Bladt et al.
CLINICAL CANCER RESEARCH (2013)
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib
Ming-Hung Huang et al.
MOLECULAR ONCOLOGY (2013)
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial
L. E. Ferri et al.
ANNALS OF ONCOLOGY (2012)
Progress in cancer therapy targeting c-Met signaling pathway
Kyung Hee Jung et al.
ARCHIVES OF PHARMACAL RESEARCH (2012)
MEK1/2 dual-specificity protein kinases: Structure and regulation
Robert Roskoski
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis
Austin M. Dulak et al.
CANCER RESEARCH (2012)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
Niantao Deng et al.
GUT (2012)
Met Kinase-dependent Loss of the E3 Ligase Cbl in Gastric Cancer
Andrea Z. Lai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma
Vipin Yadav et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Activation of the RAS/RAF/ERK Signaling Pathway Contributes to Resistance to Sunitinib in Thyroid Carcinoma Cell Lines
Annamaria Piscazzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
Wataru Okamoto et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
MET: a promising anticancer therapeutic target
Solange Peters et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation
Nathan V. Lee et al.
PLOS ONE (2012)
ERK1/2 MAP kinases: Structure, function, and regulation
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2012)
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
Xiaolei Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
Kadoaki Ohashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Molecular targeted agents for gastric and gastroesophageal junction cancer
Takashi Oshima et al.
SURGERY TODAY (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer
Sarat Chandarlapaty
CANCER DISCOVERY (2012)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi et al.
NATURE REVIEWS CANCER (2012)
Akt, FoxO and regulation of apoptosis
Xinbo Zhang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop
Zanobia A. Syed et al.
BMC CANCER (2011)
Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells
W. Okamoto et al.
BRITISH JOURNAL OF CANCER (2011)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
Jie Qi et al.
CANCER RESEARCH (2011)
MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
Jochen K. Lennerz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Discovery of a Novel B-Raf Fusion Protein Related to c-Met Drug Resistance
Roslyn Dillon et al.
JOURNAL OF PROTEOME RESEARCH (2011)
A User's Guide to the Encyclopedia of DNA Elements (ENCODE)
Richard M. Myers et al.
PLOS BIOLOGY (2011)
Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency
Ultan McDermott et al.
CANCER RESEARCH (2010)
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
Virna Cepero et al.
CANCER RESEARCH (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Molecular Predictors of Sensitivity to the MET Inhibitor PHA665752 in Lung Carcinoma Cells
Daisuke Matsubara et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dual-specificity phosphatases: critical regulators with diverse cellular targets
Kate I. Patterson et al.
BIOCHEMICAL JOURNAL (2009)
Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
Ryoichi Onozato et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer
Carrie R. Graveel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction
Andrea Bertotti et al.
SCIENCE SIGNALING (2009)
Crosstalk in Met receptor oncogenesis
Andrea Z. Lai et al.
TRENDS IN CELL BIOLOGY (2009)
Emerging roles of E2Fs in cancer: an exit from cell cycle control
Hui-Zi Chen et al.
NATURE REVIEWS CANCER (2009)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Signaling networks assembled by oncogenic EGFR and c-Met
Ailan Guo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway
H. H. L. Mak et al.
ONCOGENE (2007)
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
Shinichi Sakuramoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Lung cancer cell lines harboring MET gene amplification are dependent on met for growth and survival
Bart Lutterbach et al.
CANCER RESEARCH (2007)
From Tpr-Met to Met, tumorigenesis and tubes
P. Peschard et al.
ONCOGENE (2007)
c-Met overexpression in inflammatory breast carcinomas:: automated quantification on tissue microarrays
S. Garcia et al.
BRITISH JOURNAL OF CANCER (2007)
A module of negative feedback regulators defines growth factor signaling
Ido Amit et al.
NATURE GENETICS (2007)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
N Normanno et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
GA Smolen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Somatic mutations lead to an oncogenic deletion of Met in lung cancer
M Kong-Beltran et al.
CANCER RESEARCH (2006)
Met/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation
JV Abella et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor
SS Meng et al.
BIOCHEMICAL JOURNAL (2005)
Stat3 regulates genes common to both wound healing and cancer
DJ Dauer et al.
ONCOGENE (2005)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
How to make tubes:: signaling by the Met receptor tyrosine kinase
M Rosário et al.
TRENDS IN CELL BIOLOGY (2003)
Coordinated regulation of life and death by RB
BN Chau et al.
NATURE REVIEWS CANCER (2003)
The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors
K Nishida et al.
CANCER SCIENCE (2003)
Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions
L Lamorte et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein
P Peschard et al.
MOLECULAR CELL (2001)
Down-regulation of MET, the receptor for hepatocyte growth factor
DE Hammond et al.
ONCOGENE (2001)
SOCS proteins: Negative regulators of cytokine signaling
DL Krebs et al.
STEM CELLS (2001)
Met receptor tyrosine kinase: enhanced signaling through adapter proteins
KA Furge et al.
ONCOGENE (2000)
The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the Met receptor tyrosine kinase
CR Maroun et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Essential role of Gab1 for signaling by the c-Met receptor in vivo
M Sachs et al.
JOURNAL OF CELL BIOLOGY (2000)
Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses
U Schaeper et al.
JOURNAL OF CELL BIOLOGY (2000)
Share Paper
